This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|September 9, 2021
Thermo Fisher to Establish Single-Use Technology Site in US
Author(s)BioPharm International Editors
Thermo Fisher Scientific plans to expand its Nashville, Tenn., site by establishing a dedicated single-use technology manufacturing facility at the site, doubling capacity.
Advertisement
Thermo Fisher Scientific announced on Sept. 8, 2021 plans to establish a dedicated single-use technologies (SUT) product manufacturing facility in Nashville, Tenn. The facility, which is expected to begin construction by the second quarter of 2022, will more than double the company’s current SUT manufacturing capacity.
The Nashville site is part of a more than $650 million investment into bioprocessing production capabilities expansions, which are set to take place across 11 manufacturing sites in North America, Europe, and Asia. The investment also includes expansion projects in Logan, Utah, and Suzhou, China, along with a new SUT manufacturing site in Singapore.
The $650 million investment program also expands global production capabilities in additional bioprocessing manufacturing networks. Capacity expansion projects in Grand Island, NY, Miami, Fla., and Inchinnan, Scotland, will increase production of cell culture media (Gibco), supplements, and process liquids, as well as the manufacturing of customer-owned proprietary media formulations.
"Over the last few years, more and more biological drugs and vaccines are being manufactured utilizing the single-use platform. This has created incredible demand for our SUT products," said Michel Lagarde, executive vice-president of Thermo Fisher Scientific, in a company press release. "The site in Nashville will be critical in Thermo Fisher's global network to continue to support the biopharma industry's work in developing life-saving biologics and vaccines."
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5